Share consolidation30 Oct 2021 14:49
I don't really have an opinion, one way or the other, although I do tend to shy away from companies with billions of shares in issue (SAR obviously being the exception). It's irrational, I know, but it's also perhaps psychological. I did, however, take a keen interest in two companies' share consolidations. One was OXB, back in 2018, and the other more recently, RMM. For RMM, it's been a disaster of sorts, but not necessarily due to the consolidation. But for OXB, it's been a boon. This from their May, 2018 RNS, announcing the proposed consolidation: "The Board considers the Consolidation to be in the best interests of the Company and its Shareholders. It believes that the effect of the Consolidation will be to improve market liquidity by reducing the volatility and spread of trading activity in the Company's New Consolidated Ordinary Shares and make trading in the Company's shares more attractive to a broader range of institutional investors and other members of the investing public, both overseas and in the UK." OXB decided on a 50 to 1 ratio. The day of consolidation the SP went from 15p to 750p (actually finishing at 700p). Not wonderful, I hear you cry! But yesterday's close was 1522p ("double your money, double your fun"). I just see similarities here - 2 cutting edge biotech companies with products/IP of great interest to the larger pharmaceuticals. Credibility is key to selling oneself to the big players. Does a company operating out of a glorified garden shed in some Cambridge backwater, with 3.5 billion shares in issue, inspire confidence? IMO, a resounding "Yes!", but do the likes of GSK, AZ, Merck, etc. share my enthusiasm? Just my Saturday musing, but could the addition of PH be, indeed, to effect a share consolidation? Discuss.